SPOTLIGHT -
Efstathios Kastritis, MD, on Main Takeaways From Trial Examining Daratumumab Plus VCd to Treat AL Amyloidosis
Hematologic responses improved for patients treated with daratumumab plus VCd versus VCd alone in the ANDROMEDA trial.
Efstathios Kastritis, MD, on Main Findings From the ANDROMEDA Study in Newly Diagnosed AL Amyloidosis
The expert discussed key details from the phase 3 ANDROMEDA trial presented at the 2021 ASCO Annual Meeting.
Efstathios Kastritis, MD, on Implications of Positive Results From the Phase 3 ANDROMEDA Study
The phase 3 ANDROMEDA trial demonstrated positive efficacy and safety data in the treatment of newly diagnosed light chain amyloidosis.
Non-Secretory Myeloma: One, Two, or More Entities?
To define the differences between the subtypes of myeloma patients, not only prospective collection of clinical and laboratory data are needed, but also cytogenetics and molecular profiling.
